UBS with $26 price target which accounts for AUD$3 of the new target was expecting 6.9-7.6 months PFS
The study has reported a median rPFS of 8.8 months, representing an encouraging signal of the potential efficacy of TLX591 in this patient population.
(we do not think investors are benchmarking to Novartis' VISION trial for Pluvicto 8.7 PFS)
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS, page-6
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.73 |
Change
0.100(0.48%) |
Mkt cap ! $6.937B | |||
| Open | High | Low | Value | Volume |
| $20.83 | $20.99 | $20.40 | $17.24M | 830.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $20.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.74 | 16468 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |